Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Raynaud Clear all
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced May 21, 2026, 8:01 PM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Raynaud Disease
Interventions
0.9% nitroglycerin in TAM cream, vehicle cream
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced May 21, 2026, 8:01 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
Interventions
Blue Light Therapy, Sham Light Therapy
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions
MQX-503
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Timeline
2006
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Scleroderma
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced May 21, 2026, 8:01 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Raynaud Phenomenon
Interventions
AbobotulinumtoxinA, Saline solution
Drug · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2007 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Pletal
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
5 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Anchorage, Alaska • Fresno, California • Madera, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2005 · Synced May 21, 2026, 8:01 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
Interventions
liposomal bupivacaine
Drug
Lead sponsor
Jose Soberon, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced May 21, 2026, 8:01 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Raynaud Phenomenon, Primary Raynaud Phenomenon, Raynaud Disease, Raynaud Syndrome
Interventions
gammaCore Sapphire, Sham Device
Device
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Raynaud Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusion, Iloprost Injection, for intravenous use
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 21, 2026, 8:01 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced May 21, 2026, 8:01 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Systemic Sclerosis, Fatigue, Raynaud Phenomenon
Interventions
Apollo
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced May 21, 2026, 8:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Temanogrel, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusion, Iloprost Injection, for intravenous use
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Raynaud's Disease, Peripheral Vascular Disease
Interventions
PF-00489791
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced May 21, 2026, 8:01 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Apollo Neuro Device, Sham device
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 21, 2026, 8:01 PM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions
Nitroglycerin, Topical AmphiMatrix
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
15 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced May 21, 2026, 8:01 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Raynaud's Disease
Interventions
placebo, diosmiplex
Other · Dietary Supplement
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Peoria, Arizona • Scottsdale, Arizona • Los Alamitos, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced May 21, 2026, 8:01 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Raynaud's Disease, Raynaud Phenomena, Raynauds
Interventions
Oral treprostinil (UT-15C) sustained release tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Pletal
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
5 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
19
States / cities
Anchorage, Alaska • Fresno, California • Madera, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2005 · Synced May 21, 2026, 8:01 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
oral treprostinil, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced May 21, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced May 21, 2026, 8:01 PM EDT